Market Closed -
Japan Exchange
01:59:38 2024-06-27 EDT
|
5-day change
|
1st Jan Change
|
2,610
JPY
|
-1.14%
|
|
-1.32%
|
+26.51%
|
Fiscal Period: February |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Capitalization
1 |
17,270
|
16,488
|
11,307
|
9,578
|
9,727
|
8,775
|
Enterprise Value (EV)
1 |
23,068
|
20,970
|
16,151
|
12,897
|
12,399
|
10,652
|
P/E ratio
|
24.4
x
|
20.6
x
|
13.6
x
|
11.2
x
|
12.8
x
|
8.44
x
|
Yield
|
0.88%
|
0.92%
|
2.66%
|
1.57%
|
1.54%
|
1.93%
|
Capitalization / Revenue
|
0.55
x
|
0.51
x
|
0.36
x
|
0.29
x
|
0.29
x
|
0.22
x
|
EV / Revenue
|
0.74
x
|
0.65
x
|
0.51
x
|
0.38
x
|
0.37
x
|
0.27
x
|
EV / EBITDA
|
12.2
x
|
10.3
x
|
8.66
x
|
6.01
x
|
6.98
x
|
4.55
x
|
EV / FCF
|
-34.8
x
|
14.9
x
|
15.6
x
|
13.8
x
|
16.7
x
|
8.23
x
|
FCF Yield
|
-2.87%
|
6.72%
|
6.43%
|
7.27%
|
5.99%
|
12.2%
|
Price to Book
|
1.81
x
|
1.62
x
|
1.08
x
|
0.84
x
|
0.81
x
|
0.66
x
|
Nbr of stocks (in thousands)
|
3,812
|
3,812
|
3,757
|
3,756
|
3,757
|
3,758
|
Reference price
2 |
4,530
|
4,325
|
3,010
|
2,550
|
2,589
|
2,335
|
Announcement Date
|
5/23/19
|
5/28/20
|
5/27/21
|
5/26/22
|
5/25/23
|
5/23/24
|
Fiscal Period: February |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net sales
1 |
31,222
|
32,042
|
31,603
|
33,595
|
33,897
|
39,900
|
EBITDA
1 |
1,892
|
2,030
|
1,865
|
2,145
|
1,776
|
2,342
|
EBIT
1 |
1,044
|
1,205
|
1,030
|
1,275
|
935
|
1,559
|
Operating Margin
|
3.34%
|
3.76%
|
3.26%
|
3.8%
|
2.76%
|
3.91%
|
Earnings before Tax (EBT)
1 |
1,167
|
1,271
|
1,443
|
1,476
|
1,312
|
1,661
|
Net income
1 |
711
|
801
|
836
|
852
|
759
|
1,039
|
Net margin
|
2.28%
|
2.5%
|
2.65%
|
2.54%
|
2.24%
|
2.6%
|
EPS
2 |
185.8
|
210.1
|
221.6
|
226.8
|
202.0
|
276.5
|
Free Cash Flow
1 |
-662.6
|
1,409
|
1,039
|
937.6
|
743.1
|
1,295
|
FCF margin
|
-2.12%
|
4.4%
|
3.29%
|
2.79%
|
2.19%
|
3.24%
|
FCF Conversion (EBITDA)
|
-
|
69.4%
|
55.69%
|
43.71%
|
41.84%
|
55.28%
|
FCF Conversion (Net income)
|
-
|
175.89%
|
124.24%
|
110.05%
|
97.91%
|
124.6%
|
Dividend per Share
2 |
40.00
|
40.00
|
80.00
|
40.00
|
40.00
|
45.00
|
Announcement Date
|
5/23/19
|
5/28/20
|
5/27/21
|
5/26/22
|
5/25/23
|
5/23/24
|
Fiscal Period: February |
2021 S1
|
2022 S1
|
2022 Q3
|
2023 Q1
|
2023 S1
|
2023 Q3
|
2024 Q1
|
2024 S1
|
2024 Q3
|
---|
Net sales
1 |
15,522
|
16,812
|
8,399
|
8,563
|
16,978
|
8,449
|
8,721
|
17,450
|
11,319
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
395
|
648
|
360
|
239
|
465
|
240
|
294
|
603
|
475
|
Operating Margin
|
2.54%
|
3.85%
|
4.29%
|
2.79%
|
2.74%
|
2.84%
|
3.37%
|
3.46%
|
4.2%
|
Earnings before Tax (EBT)
1 |
708
|
784
|
396
|
333
|
624
|
373
|
374
|
775
|
499
|
Net income
1 |
434
|
445
|
225
|
208
|
374
|
223
|
211
|
444
|
368
|
Net margin
|
2.8%
|
2.65%
|
2.68%
|
2.43%
|
2.2%
|
2.64%
|
2.42%
|
2.54%
|
3.25%
|
EPS
2 |
114.8
|
118.6
|
59.73
|
55.39
|
99.65
|
59.35
|
56.42
|
118.3
|
97.94
|
Dividend per Share
|
20.00
|
20.00
|
-
|
-
|
20.00
|
-
|
-
|
20.00
|
-
|
Announcement Date
|
9/30/20
|
9/30/21
|
1/11/22
|
7/4/22
|
10/3/22
|
1/10/23
|
7/3/23
|
10/2/23
|
1/10/24
|
Fiscal Period: February |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
---|
Net Debt
1 |
5,798
|
4,482
|
4,844
|
3,319
|
2,672
|
1,877
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
3.064
x
|
2.208
x
|
2.597
x
|
1.547
x
|
1.505
x
|
0.8015
x
|
Free Cash Flow
1 |
-663
|
1,409
|
1,039
|
938
|
743
|
1,295
|
ROE (net income / shareholders' equity)
|
7.54%
|
8.12%
|
8.09%
|
7.75%
|
6.29%
|
8.17%
|
ROA (Net income/ Total Assets)
|
2.51%
|
2.87%
|
2.35%
|
2.76%
|
2.06%
|
3.29%
|
Assets
1 |
28,297
|
27,870
|
35,550
|
30,819
|
36,757
|
31,544
|
Book Value Per Share
2 |
2,505
|
2,668
|
2,791
|
3,031
|
3,207
|
3,523
|
Cash Flow per Share
2 |
1,392
|
1,494
|
1,864
|
2,128
|
1,715
|
2,049
|
Capex
1 |
1,084
|
451
|
470
|
322
|
311
|
302
|
Capex / Sales
|
3.47%
|
1.41%
|
1.49%
|
0.96%
|
0.92%
|
0.76%
|
Announcement Date
|
5/23/19
|
5/28/20
|
5/27/21
|
5/26/22
|
5/25/23
|
5/23/24
|
|
1st Jan change
|
Capi.
|
---|
| +26.51% | 61.04M | | -12.65% | 8.23B | | +33.84% | 1.35B | | -9.90% | 350M | | +6.86% | 279M | | +8.89% | 221M | | -44.11% | 83.2M | | -34.86% | 62.09M |
Retail - Drugs without Grocery
|